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BACKGROUND: To analyse the discriminative impact of osteopontin (OPN) and activated leukocyte cell adhesion molecule (ALCAM),
combined with human epidermal growth factor 2 (HER2) and oestrogen receptor (ER) in breast cancer.
METHODS: Osteopontin, ALCAM, HER2 and ER mRNA expression in breast cancer tissues of 481 patients were analysed (mRNA
microarray analysis, kinetic RT–PCR). Hierarchical clustering was performed in training cohort A (N¼100, adjuvant treatment) and
validation cohorts B (N¼200, no adjuvant treatment, low-risk) and C (N¼181, adjuvant treatment, high-risk).
RESULTS: Negative/low ER and HER2, high OPN and low ALCAM mRNA expression helped to identify patients at particularly high
risk, showing shorter DFS, Po0.001, and OAS, P¼0.001. Although both validation cohorts showed diverse risk and treatment
profiles, this marker constellation was concordantly associated with shorter DFS and OAS (Po0.001 and P¼0.075 for cohort B and
P¼0.043 and Po0.001 for cohort C, respectively). In multivariate analysis, this algorithm was the main independent prognostic
factor. Cohort B: DFS, P¼0.0065, OAS, not significant; cohort C: DFS, P¼0.026, OAS, Po0.001.
CONCLUSION: Activated leukocyte cell adhesion molecule and OPN mRNA expression has a strong discriminative impact on survival
within cancer patients with low or negative expression of ER and HER2, so called ‘high-risk’ breast cancers, and might help in
identifying patients who could benefit from new treatment approaches like targeted therapies in the adjuvant setting.
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Human breast cancer represents a heterogeneous group of
tumours that are diverse in behaviour, outcome and response to
therapy. Tumours with hormone receptor and human epidermal
growth factor 2 (HER2) negativity are defined as ‘high-risk’
tumours, because of their aggressive growth and resistance to
common treatment strategies. However, not all of these tumours
behave poorly (Rakha et al, 2007). This indicates the underlying
heterogeneous nature of these breast cancers, which should
therefore be treated by individualised therapy regimens and new
treatment approaches in case of assumed therapy resistance.
Up to date, all currently available gene signatures have failed
to discriminate oestrogen receptor (ESR1)-negative/HER2-nega-
tive breast cancer with poor prognosis from those with relatively
good outcome (Desmedt et al, 2008).
We conducted this study to evaluate the discriminative ability of
two experimental markers, osteopontin (SPP1) and activated
leukocyte cell adhesion molecule (ALCAM), both regulated by
transcription factor Fra-2 (Andersen et al, 2002; Milde-Langosch
et al, 2008), in combination with HER2 and ER. In breast cancer
cell lines, OPN has been shown to enhance replication, angio-
genesis, evasion from apoptosis, and invasive potential, probably
by affecting the expression of several genes, with special reference
to the vascular endothelial growth factor gene (Cook et al, 2005;
Chakraborty et al, 2008). In breast cancer patients, high OPN
protein levels in tumour tissue and blood samples were associated
with poor prognosis and disease progression. Beyond that, recent
data suggest that patients with OPN overexpression develop
predominantly triple-negative tumours (McAllister et al, 2008).
Despite various published data indicating the negative prognostic
effect of OPN in breast cancer, no clinical use has been described
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syet. Due to its known tumour biological functions, OPN appears to
have the ability to identify high-risk tumours, and was therefore
included into our model (Rudland et al, 2002).
The adhesion molecule ALCAM shows an altered expression
in breast cancer, and has been described as a prognostic and
predictive marker (Kristiansen et al, 2003; King et al, 2004;
Weichert et al, 2004; Swart et al, 2005; Verma et al, 2005;
Burkhardt et al, 2006; Ihnen et al, 2008). The possibility that
ALCAM might be useful in characterising different subsets of
breast carcinomas was already indicated by Doane et al (2006),
who, by genome-wide expression analysis and unsupervised
hierarchical clustering, identified two subgroups of ER/PR-
negative mammary carcinomas, which differed in the expression
of several genes, including ALCAM.A sALCAM and SPP1 are
characterised by a relatively high dynamic range of expression
levels, which were weakly and inversely associated with each other,
they were found to be suitable as potential molecular discrimina-
tive markers for our study. We performed mRNA microarray
analysis and hierarchical cluster analysis, based on SPP1, ALCAM,
ESR1 and HER2, by using cohort A as a training cohort (N¼100,
treated with adjuvant chemotherapy, medium-risk). Based on
these results, we generated a decision tree, which was applied to
two independent cohorts (cohort B, N¼200, patients without
adjuvant treatment, low-risk, and cohort C, N¼181, patients
treated in the adjuvant setting, high-risk) in order to verify our
findings. By this approach, we consistently observed in all the
three cohorts that the level of SPP1 and ALCAM mRNA expression
enables the discrimination of good vs bad outcome in all
‘high-risk’ breast cancer patients showing low or no ESR1 and
HER2 expression.
MATERIALS AND METHODS
Patients
All patient and tumour characteristics are shown in Table 1.
Cohort A showed a normally distributed risk profile. All patients
were treated with taxane-free chemotherapy and endocrine
therapy according to international recommendations. Cohort B
was characterised by a low-risk profile due to node negativity,
and therefore the patients did not receive any systemic therapy.
Cohort C showed a relatively high-risk profile, characterised
by node positivity and/or greater tumour size. The latter patients
were treated in the Hellenic Cooperative Oncology Group
(HeCOG) 10/97 randomised trial with chemotherapy and endo-
crine therapy, depending on receptor status. None of the patients
within all the three cohorts received trastuzumab. In the first two
cohorts, fresh-frozen tissue (FFT) was analysed, whereas in cohort
C, formalin-fixed paraffin-embedded (FFPE) material was used.
Informed consent for the scientific use of tissue materials, which
was approved by the local ethics committees, was obtained from all
patients. The study was performed in accordance to the principles of
the declaration of Helsinki and REMARK criteria (McShane et al,
2005). Histopathological information was collected from the original
pathology reports. The study design is described by Figure 1A.
Cohort characteristics: cohort A (training cohort)
Fresh-frozen tissue from 100 breast cancer patients treated with
adjuvant chemotherapy were collected after surgery, snap-frozen
and stored in liquid nitrogen. All patients were treated at the
Department of Gynaecology of the University Medical Centre
Hamburg Eppendorf, Germany between 1992 and 2002. The median
follow-up time was 81 months (range, 7–168 months). No
radiotherapy, neoadjuvant chemotherapy or endocrine therapy had
been administered before surgery. The patients received the following
adjuvant chemotherapy regimens: epirubicin/cyclophosphamide
(EC), 37 cases; cyclophosphamide/methotrexate/fluorouracil (CMF),
44 patients; epirubicin (E) or epirubicin/cyclophosphamide/fluoro-
uracil (FEC), 3 cases; and unknown, 16 cases.
Table 1 Patient characteristics
Cohort A
(training)
N¼100
Cohort B
(validation)
N¼200
Cohort C
(validation)
N¼181
n (%) n (%) n (%)
Age (years)
Median 52 60 52
Range 29–73 34–89 22–76
Menopausal status
Pre-/peri-menopausal 63 (63) — 90 (50)
Post-menopausal 24 (24) — 91 (50)
Unknown 13 (13) — 0
Histological type
Ductal 73 (73) 127 (64) 136 (75)
Lobular 15 (15) 35 (18) 22 (12)
Others 11 (11) 15 (13) 23 (13)
Unknown 1 (1) 23 (12) 0
Tumour size (stage)
p2cm (pT1) 24 (24) 112 (56) 57 (32)
2–5cm (pT2) 63 (63) 85 (43) 89 (49)
45cm (pT3–4) 12 (12) 3 (2) 35 (19)
Unknown 1 (1) 0 0
Grade
I–II 39 (39) 163 (82) 86 (48)
III–undifferentiated 59 (59) 37 (19) 94 (52)
Unknown 2 (2) 1 (1)
Lymph nodes
Positive nodes 42 (42) 0 178 (98)
1–3 — 0 39 (22)
X4 — 0 139 (77)
Negative nodes 58 (58) 200 (100) 3 (2)
ER status
Positive 65 (65) 163 (82) 128 (71)
Negative 32 (32) 37 (19) 50 (28)
Unknown 3 (3) 0 3 (2)
PR status
Positive 54 (54) 144 (72) 109 (60)
Negative 43 (43) 56 (28) 66 (36)
Unknown 3 (3) 0 6 (3)
HER2 status
Positive — 26 (13) 53 (29)
Negative — 165 (83) 124 (68)
Intermediate — 9 (5) —
Unknown 100 (100) 0 4 (2)
Adjuvant RT
Yes 58 (58) 125 (63) 141 (78)
No 19 (19) 75 (37) 39 (22)
Unknown 23 (23) 0 1 (1)
Adjuvant HT
Yes 54 (54) 0 168 (93)
No 35 (35) 200 (100) 11 (6)
Unknown 11 (11) 0 2 (1)
Follow-up
Recurrence 33 (33) 58 (29) 55 (30)
Died of disease 20 (20) 57 (29) 37 (20)
Abbreviations: ER¼oestrogen receptor; HER2¼human epidermal growth factor 2;
HT¼hormone therapy; PR¼progesterone receptor; RT¼radio therapy.
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This population-based cohort consisted of 200 consecutive lymph
node-negative breast cancer patients, treated at the Department of
Obstetrics and Gynaecology of the Johannes Gutenberg University,
Mainz between 1988 and 1998. The median age of the patients at
surgery was 60 years (range, 34–89 years). The median time of
follow-up was 92 months. Patients did not receive any systemic
therapy in the adjuvant setting. Patients were treated either with
modified radical mastectomy (N¼75) or with breast-conserving
surgery followed by irradiation (N¼125), and did not show
evidence of regional lymph node or distant metastases at the time
of surgery.
Cohort characteristics: cohort C (validation cohort)
Formalin-fixed paraffin-embedded tissues of 181 primary breast
cancer patients who were part of the HeCOG 10/97 trial population
were collected. The median follow-up time was 97 months. The
HeCOG 10/97 trial randomised a total of 595 high-risk (T1-3N1M0
or T3N0M0) breast cancer patients in the period 1997–2000, to
receive either four cycles of E followed by four cycles of intensified
CMF (E-CMF) or three cycles of epirubicin followed by three cycles
of paclitaxel (T) and three cycles of intensified CMF (E-T-CMF), as
previously described (Fountzilas et al, 2005).
RNA isolation from FFT (cohorts A and B)
Approximately, 50mg of fresh-frozen breast tumour tissue was
crushed in liquid nitrogen. Tumour cell content exceeded 40% in
all the samples, as shown by H&E staining of cryo-cut sections.
RLT-Buffer (QIAGEN, Hilden, Germany) was added and the
homogenate was centrifuged through a QIAshredder column
(QIAGEN). From the eluate, total RNA was isolated using the
RNeasy Kit (QIAGEN) according to the manufacturer’s instruc-
tions. The RNA yield was determined by UV absorbance and its
quality was assessed by evaluating the ribosomal RNA band
integrity on an Agilent 2100 Bioanalyzer RNA 6000 LabChip kit
(Agilent Technologies, Palo Alto, CA, USA).
Microarray analysis (cohorts A and B)
The Affymetrix (Santa Clara, CA, USA) HG-U133A array and
GeneChip System were used to quantify the relative transcript
abundance in the breast cancer tissues. Starting with 5mg total
RNA labelled cDNA was prepared using the Roche Microarray
cDNA Synthesis (Roche Diagnostics GmbH, Roche Applied
Science, Mannheim, Germany), Microarray RNA Target Synthesis
(T7) and Microarray Target Purification Kit, according to the
manufacturer’s instructions. In the analysis settings, the global
scaling procedure was chosen, which multiplied the output signal
intensities of each array to a mean target intensity of 500. Samples
with suboptimal average signal intensities (i.e., scaling factors 425
or GAPDH 30/50 ratios 45) were re-labelled and re-hybridised on
new arrays.
RNA isolation from FFPE tissue and kRT–PCR assessment
(cohort C)
Intact RNA with high quality, as determined by analysis of the
housekeeping gene RPL37A, was isolated from 181 FFPE samples
from the HeCOG cohort by using an experimental method based
on proprietary magnetic beads from Siemens Healthcare Diag-
nostics Products GmbH (Cologne, Germany), as previously
described (Pentheroudakis et al, 2009). In total, 98 patients were
treated with E-CMF and 83 with E-T-CMF. The number of
malignant cells represented at least 30% of all nucleated cells per
section, as verified by H&E staining. Kinetic reverse transcription-
polymerase chain reaction (kRT–PCR) was applied for the
assessment of mRNA expression of ALCAM, SPP1, HER2 and
ESR1, using the following TaqMan-based primer/probe sets:
ALCAM probe 50-CCTTGCCGCAAAGTGTGTAACGGAAT-30
Forward primer 50-CGCAAGTGTAAGAAGTGCGAA-30
Reverse primer 50-CGTAGCATTTATGGAGAGTGAGTCT-30
SPP1 probe 50-CTCAAAGGTACTCCCTCCTCCCGGG-30
Forward primer 50-CGGTTATGTCATGCCAGATACAC-30
Reverse primer 50-GAACTGAGACCCACTGAAGAAAGG-30
HER2 probe 50-ACCAGGACCCACCAGAGCGGG-30
Forward primer 50-CCAGCCTTCGACAACCTCTATT-30
Reverse primer 50-TGCCGTAGGTGTCCCTTTG-30
ESR1 probe 50-CACAGACTGCTTTGCCTGCATGAATTTC-30
Forward primer 50-GAGGCTGCTCAGGACCTAAGG-30
Reverse primer 50-GAGTAACACATGCTCCACTGTCATT-30
Forty cycles of amplification were applied and the cycle
threshold (CT) values of the target genes were identified. Cycle
threshold values were normalised by subtracting the CT value of
the housekeeping gene RPL37A from the CT value of the target
gene (DCT). RNA results were then reported as 40 DCT values,
which would correlate proportionally to the mRNA expression
level of the target gene.
Human reference total RNA pooled from 10 human cell lines
(Stratagene, La Jolla, CA, USA) was used as a positive control.
RNA-free DNA extracted from tumour tissues was used as a
negative control.
Statistical analysis
Fisher’s exact test was applied to compare the clinical and
pathological factors with molecular gene expression (low vs high).
Spearman’s rank correlation was used as a measure of association
Training cohort
Cohort A (N=100, CTX)
Affymetrix data
Hierarchical clustering
Generation of a decision tree
Validation cohort  II
Cohort C (N=181, CTX)
kRT–PCR
Validation cohort  I
Cohort B (N=200, untreated)
Affymetrix data
All cases
Her2-positive
group
Her2-negative
group
ER positive
(group 1)
ER negative
OPN low
(group 3)
OPN high
ALCAM high
(group 3)
ALCAM low
(group 2)
Figure 1 Schematic figure of the experimental design, showing
characteristics of all the three cohorts analysed in this study
(A). Representation of the decision tree, which was generated based on
data obtained from the cluster analysis of the training cohort A (B).
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using Kaplan–Meier curves and compared using the log-rank test.
Disease-free survival was defined as the interval from study
entry to disease recurrence or death from any cause. Overall
survival was measured from study entry until death from any
cause. Surviving patients were censored at the date of last contact.
For prognosis evaluation the following variables were included
into the analysis of cohort A: age (o52 years vs 52 years and
older), tumour size (o2cm vs 2–5cm vs 45cm), tumour grade
(I–II vs III), histological type (ductal vs lobular vs others), nodal
involvement vs nodal-negative tumours, and immunohisto-
chemical ER and PR status (negative vs positive). In cohort B,
age at diagnosis (o60 years vs the median age of 60 years and
older), tumour size (p2cmvs 42cm), immunohistochemical ER,
PR and HER2 status (negative vs positive), and tumour grade (I vs
II vs III) were compared. In the analysis of cohort C, we included
the randomisation group (E-T-CMF vs E-CMF), age, tumour size
(o2cmvs 2–5cm vs 45cm), histological type (ductal vs lobular
vs mixed vs other), adjuvant endocrine treatment (yes vs no),
radiotherapy (yes vs no), ER/PR status (negative vs positive), as
well as menopausal status (pre vs post), number of positive nodes
(0–3 vs X4) and tumour grade (I–II vs III-undifferentiated) into
our correlations. The Cox proportional hazards model was used to
assess the strength of the association of OAS and DFS with clinical
and histological variables in the presence of group classification.
Backward selection procedure was used, with removal criterion
P40.10, to identify a subclass of significant clinical variables.
The level of statistical significance was P¼0.05 for all tests. All
P-values were two-sided. The results of this study were presented
according to the REMARK criteria for tumour marker studies
(McShane et al, 2005). The statistical analysis was conducted using
SPSS 15.0 for windows or JMP 5.0.1.2 programs. Hierarchical
cluster analysis, decision tree model and Kaplan–Meier analysis in
cohorts A and B were performed using the JMP 5.0.1.2 program.
For the initial cluster analysis in the finding cohort, the ESR1 and
HER2 expression values were scaled down by a factor of 5
compared with the ALCAM and SPP1 values to reduce their
corruptive effect on data analysis because of their relatively
high expression levels. For separation of all HER2-positive cases
from clusters I–III in cohort A, we used a cutoff value of 6000 at
TGT500. For the decision tree model in cohort B, we used
predefined cutoffs of 6000 for HER2 and 1200 for ESR1. For the
distinction of SPP1 and ALCAM levels in cohort B, we used the
objective 50th percentile in order to define low and high mRNA
expression of ALCAM and SPP1 (predefined cutoffs for SPP1 was
2181.0 and for ALCAM was 3193.5).
As for cohort C, predefined cutoffs were used for ESR1 and
HER2 mRNA expression, which were close to the 25th and 75th
percentile, respectively. The median normalised DCT value for
ESR1 was 35.58 (range, 28.51–40.30), for HER2 was 35.48 (range,
30.35–41.51), for ALCAM was 34.55 (range, 27.09–37.09) and for
SPP1 was 31.38 (range, 26.52–41.95).
RESULTS
Cohort A: hierarchical cluster analysis of the training
cohort
On the basis of Ward correlation, a hierarchical cluster analysis
was performed. Focused on SPP1, ALCAM, HER2 and ESR1 mRNA
expression, the analysis revealed three main clusters (Figure 2A).
Cluster I was characterised by relatively high ESR1 expression,
variable HER2 and ALCAM expression, and weak or negative SPP1
expression.
Cluster II was characterised by predominantly negative ESR1
and HER2 expression, high SPP1, and weak or negative ALCAM
expression.
Cluster III showed variable ESR1 and HER2 expression and
positive SPP1 and ALCAM expression levels. When we analysed
these clusters with respect to the occurred events, patients who
suffered from recurrence were predominantly found in cluster II.
In clusters I and III the recurrence rates were lower, and most
of the events occurred in cases expressing high HER2 mRNA
levels (Figure 2A, purple bars on the left side).
We therefore separated the HER2-positive cases from clusters
I–III to build a HER2-positive group, containing all HER2-positive
cases, and we designated three other groups (groups 1–3), which
were based on our clusters henceforth containing only cases with
low/negative HER2 expression. Each of these groups showed a
specific distribution of ER, HER2, ALCAM and OPN expression
(Figure 2D).
When we performed a Kaplan–Meier analysis including all the
four groups (groups 1–3 and the HER2-positive group), group 2
(characterised by weak or negative ER and HER2 expression, and
high OPN and low ALCAM expression) turned out to contain
predominantly high-risk cases with highly significant differences
in DFS (Po0.001) and OAS (P¼0.001) compared with all the other
groups (Figure 2B and C, respectively). A detailed pairwise analysis
within all the groups revealed further significant differences for
DFS and OAS. These results are shown in Table 2a.
Cohort B: mRNA microarray analysis and decision tree
application
Based on the results of the hierarchical clustering in cohort A,
we generated a decision tree model (Figure 1B). By this approach,
we defined four different groups within cohort B: the HER2-
positive group: n¼20 (HER2-positive tumours); group 1: n¼156
(HER2-negative, ER-positive tumours with intermediate ALCAM
and low OPN expression); group 2: n¼14 (HER2/ER-negative
tumours with high OPN and low ALCAM expression); group 3:
n¼10 (HER2/ER-negative tumours with predominantly higher
OPN and ALCAM expression). Kaplan–Meier curves for DFS
(Figure 3A) differed significantly (Po0.001), while the differences
in OAS showed a trend of being significant between all groups
(P¼0.075; Figure 3B). Statistically significant differences in
pairwise analysis between all generated groups are presented in
Table 2b. By multivariate analysis including grading, tumour size
and ER immunohistochemical (IHC) status, the decision tree
classification was shown to be the only significant independent
predictor of DFS (P¼0.0065), whereas histological grading
(P¼0.060), ER status (P¼0.107) and tumour size (P¼0.235) lost
their significance (data not shown). When comparing the SPP1
mRNA expression levels with clinicopathological data, no signi-
ficant associations with immunohistochemically determined ER,
PR or HER2 status, clinical stage, age, and histological grading
were found (data not shown). In contrast, significant positive
correlations of high ALCAM expression levels with low grading
(P¼0.009), smaller tumour size (P¼0.023) and positive PR (IHC)
results (P¼0.027) were obtained, whereas the association with ER
(IHC) positivity did not reach statistical significance (P¼0.101).
Cohort C: kRT–PCR and decision tree application
In order to test the discriminative value of our algorithm in FFPE
tissue, the four markers were analysed in cohort C by using
kRT–PCR. As former studies have shown that mRNA quantifica-
tion using mRNA microarray analysis and RT–PCR resulted in
similar gene expression levels (Modlich et al, 2004; Zamagni et al,
2009), we found it reasonable to use cohort C for verification.
Based on the same decision tree algorithm that we used in cohort B
(Figure 1B), 32 tumours were classified in the HER2-positive
group, 111 in group 1 (HER2-negative, ER-positive tumours with
intermediate ALCAM and low OPN), 17 in group 2 (HER2/ER-
negative tumours with high OPN and low ALCAM expression) and
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Figure 2 Cohort A (training cohort) hierarchical cluster analysis based on OPN (SPP1), ALCAM, ER (ESR1) and HER2 mRNA expression levels (A),
revealing three main clusters (I–III). In the coloured map, gene expression levels ranged from low (green), to moderate (white), to high (red). Cases with
recurrences during follow-up are highlighted with coloured horizontal bars on the left. Tumours with high HER2 expression are marked on the left margin of
the graph (purple bars). Based on clusters I–III and after separating HER2-positive cases, four groups (groups 1–3 and the HER2-positive group) were
identified (D) (median values and s.d are given). (B) and (C) show Kaplan–Meier curves for DFS and OAS of the four groups, with group 2 being the ‘high-
risk’ group characterised by ER/HER negativity, high OPN and low ALCAM mRNA expression.
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higher OPN and ALCAM expression). Kaplan–Meier curves for
DFS (Figure 4A) and OAS (Figure 4B) differed significantly
between all the four groups (DFS, P¼0.043 and OAS, Po0.001,
respectively). For pairwise comparisons see Table 2c.
When groups 1, 3 and the HER2-positive group were combined
and compared with group 2, significant differences for DFS
(P¼0.013) and OAS (P¼0.001) were observed (data not shown).
The discriminative value of our gene-set algorithm was also
examined with regard to patients, who were randomised to the
paclitaxel- or non-paclitaxel-containing treatment arm in the
HeCOG 10/97 trial. Patients whose tumours showed ER/HER2
negativity, and high OPN and low ALCAM expression (group 2)
turned out to be the group having the highest risk for shorter DFS
and OAS compared with all the other groups regardless of the
administered therapy (see Table 2d and e). Multivariate analysis
revealed that only the algorithm classification and the number
of positive nodes (X4) are independent predictors of outcome
in this cohort (Table 3). Group 2 was associated with an increased
risk of death (HR¼3.94, 95% CI 1.92–8.09, Po0.001) and
relapse (HR¼2.18, 95% CI 1.10–4.34, P¼0.026). Four or more
positive nodes were associated with shorter OAS (HR¼3.21, 95%
CI 1.14–9.01, P¼0.027) and DFS (HR¼2.21, 95% CI 1.05–4.65,
P¼0.038).
Comparison of ALCAM expression with clinicopathological
data did not show any significant associations (data not shown).
Osteopontin expression was not found to be associated with ER
or HER2, nor with any other clinicopathological factors.
DISCUSSION
The results of the present hypothesis-generating study show that
the application of the two, in this context newly discovered,
molecular markers, ALCAM and OPN, could discriminate prog-
nostic subgroups within HER2- and ER-negative early breast
cancer patients. These results were detectable regardless of the
administered adjuvant therapy regimens or patients’ risk profiles,
and might therefore help identify receptor-negative breast cancer
patients characterised by a particular unfavourable outcome.
Although we used different cohorts and analysed gene expression
by two methods, we were able to show this effect in each of these
three cohorts, which to our opinion strengthens our algorithm,
even though our results have to be validated in a larger cohort with
a prospective design. We became interested in ALCAM and OPN
in the course of our previous studies on the AP-1 protein Fra-2, as
both genes are regulated by this transcription factor (Andersen
et al, 2002; Milde-Langosch et al, 2008). Based on previous OPN
studies and own findings regarding the role of ALCAM in breast
cancer (Ihnen et al, 2008), we decided to evaluate the discrimi-
native value of these genes in combination with HER2 and ESR1 in
Table 2 Pairwise comparison of DFS and OAS in groups 1–3 and the
HER2-positive group generated by our algorithm
HR 95% CI P
(a) Cohort A
DFS
Group 2 vs group 1 4.58 1.96–10.67 o0.001
OAS
Group 2 vs group 1 5.76 2.10–15.77 0.001
Group 2 vs group 3 9.01 1.13–71.40 0.038
HER2 pos. vs group 1 1.43 1.01–2.03 0.047
(b) Cohort B
DFS
Group 2 vs HER2 positive. 1.79 1.07–3.00 0.020
Group 2 vs group 1 8.25 3.62–18.79 o0.001
Group 2 vs group 3 3.79 1.18–12.20 0.017
(c) Cohort C
DFS
Group 2 vs group 1 2.58 1.26–5.25 0.009
OAS
Group 2 vs HER2 positive. 3.55 1.40–9.01 0.008
Group 2 vs group 1 4.71 2.21–10.04 o0.001
(d) Cohort C (paclitaxel group)
OAS
Group 2 vs group 1 4.44 1.20–16.47 0.026
(e) Cohort C (non-paclitaxel group)
DFS
Group 2 vs group 1 3.24 1.32–7.94 0.010
Group 2 vs group 3 5.42 1.12–26.25 0.036
OAS
Group 2 vs HER2 positive. 3.30 1.02–10.72 0.047
Group 2 vs group 1 5.08 1.97–13.09 0.001
Group 2 vs group 3 12.55 1.54–102.67 0.018
Abbreviations: CI¼confidence interval; DFS¼disease-free survival; HER2¼human
epidermal growth factor 2; HR¼hazards ratio; OAS¼overall survival. Only
significant differences are given for all three cohorts (A, B and C).
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Figure 3 Kaplan–Meier curves of cohort B (first validation cohort) showing DFS (A) and OAS (B) in groups 1–3 and the HER2-positive group classified
by their HER2, ER, OPN and ALCAM expression levels as follows: HER2 pos.: HER2-positive tumours; group 1: HER2-negative/ER-positive tumours;
group 2: ER/HER2-negative, OPN-high, ALCAM low tumours (high-risk group); group 3: ER/HER2-negative, OPN-low tumours or OPN-high/ALCAM-high
tumours.
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san effort to identify breast cancer subgroups, in which SPP1 and
ALCAM are of particular relevance as we attributed to these genes
a certain discriminative impact.
The HER2 gene amplification and/or protein overexpression
is found in 15–30% of all invasive breast cancers and has been
associated with more aggressive disease and shorter disease-free
survival, through activation of several intracellular pathways
ultimately affecting cell proliferation, survival, motility and
adhesion (Baselga et al, 2005). Based on our hierarchical cluster
analysis we excluded all HER2-positive cases from each cohort to
analyse the outcome in this group separately, taking into account
the high impact of HER2 overexpression on survival. As expected,
an unfavourable prognosis was seen in the HER2-positive
group, but patients expressing no HER2 but high OPN and low
ALCAM (group 2) were found to have an even worse survival
(see Figures 2–4).
Regarding the ER expression status, it is well known that high
ER expression is associated with beneficial prognosis. In our study,
improved survival was seen in patients whose tumours expressed
high ER levels, as shown in cluster I and concordantly in group 1,
within all the three cohorts (see Figures 2–4). To date, it is
standard to determine the ER expression status by IHC methods.
Recent findings have shown that RT–PCR determination of ER
expression is superior to ligand binding or IHC approaches for
prediction of distant recurrence-free survival (Kim et al, 2006).
Referring to that, we saw that ER determination by kRT–PCR
correlates moderately with IHC results (Kim et al, 2006;
Pentheroudakis et al, 2009). Based on different gene expression
levels, we obtained besides the HER2 positive. group and group 1,
another two additional groups (group 2 and group 3) (see Figures
2–4). Group 3 showed low ER and HER2 and high OPN and
ALCAM expression levels. Group 2 was characterised by the same
expression pattern, but showed, unlike group 3, low ALCAM
expression levels. Group 3 exhibited survival rates similar to those
observed in the favourable prognosis group 1; group 2 showed the
poorest outcome compared with all the groups. These observations
appear to suggest that ALCAM, or some co-regulated gene, has
beneficial effects on receptor-negative and high SPP1-expressing
tumours. Although high ALCAM expression levels have been
associated with better outcome and might be predictive for
chemotherapy response in breast cancer, the underlying biological
mechanism for survival benefit still remains unclear (King et al,
2004; Ihnen et al, 2008). As known, OPN expression has been
associated with worse outcome and aggressive tumour growth. Our
observations, however, indicate that high OPN expression per se
may not necessarily function as a driving force of increased
aggressiveness, as shown in group 3. It might be possible that OPN
shows adverse potential in combination with specific marker
expression patterns, like low ALCAM expression levels. The
previous observation that OPN expression seems to be associated
with the increased appearance of predominantly triple-negative
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Figure 4 Kaplan–Meier curves of cohort C (second validation cohort) showing DFS (A) and OAS (B) in groups 1–3 and the HER2-positive group
classified by their HER2, ER, OPN and ALCAM expression levels as follows: HER2 pos., HER2-positive tumours; group 1: HER2-negative/ER-positive
tumours; group 2: ER/HER2-negative, OPN-high, ALCAM-low tumours (high-risk group); group 3: ER/HER2-negative, OPN-low tumours or OPN-high/
ALCAM-high tumours.
Table 3 Cox regression analysis including conventional prognostic
markers and groups 1–3 and the HER2-positive group of cohort C based
on our four-gene algorithm
HR 95% CI P
(a) OAS
Grade
I–II 1
III—undifferentiated 1.72 0.92–3.30 0.086
Positive nodes
0–3 1
X4 3.21 1.14–9.01 0.027
Algorithm classification
Group 1+3+HER2 positive. 1
Group 2 3.94 1.92–8.09 o0.001
Treatment group
E-T-CMF 1
E-CMF 1.18 0.64–2.17 0.603
(b) DFS
Grade
I–II 1
III–undifferentiated 1.45 0.87–2.42 0.157
Positive nodes
0–3 1
X4 2.21 1.05–4.65 0.038
Algorithm classification
Group 1+3+HER2 positive. 1
Group 2 2.18 1.10–4.34 0.026
Treatment group
E-T-CMF 1
E-CMF 1.08 0.65–1.80 0.767
Abbreviations: CI¼confidence interval; DFS¼disease-free survival; E-CMF¼
epirubicin-cyclophosphamide, methotrexate and fluorouracil; E-T-CMF¼epirubicin-
paclitaxel-cyclophosphamide, methotrexate and fluorouracil; HER2¼human epider-
mal growth factor 2; HR¼hazards ratio; OAS¼overall survival. Only the presented
algorithm and the number of positive nodes (X4) are independent predictors of
outcome in this cohort.
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stumours (Rudland et al, 2002; Cook et al, 2005; McAllister et al,
2008) appears to be reflected by our results showing that ER- and
HER2-negative tumours predominantly express high OPN levels
(see Figure 2A, cluster II and Figure 2D). Of note, our experimental
study design does not discriminate between splice variants or the
origin of the OPN mRNA expression. This means it remains
unclear whether OPN is expressed by tumour cells, stromal
fibroblasts or inflammatory cells.
As regard the technical aspect of this study, it should be added
that the comparability of mRNA microarray data (cohorts A
and B) with RT–PCR data (cohort C) regarding gene expression
levels might be a subject of discussion. But as other studies have
shown that the RNA quantification by using mRNA microarray
analysis and RT–PCR resulted in similar gene expression levels
(Modlich et al, 2004; Zamagni et al, 2009), we deemed it
appropriate to include the RT–PCR results of cohort C into our
study as a second verification cohort. Although we agree that the
comparability of mRNA expression with protein expression levels
might be of interest and could be a subject of discussion, we
refrained from including western blot and IHC methods into this
study. Our group and others have shown that there is a good
correlation between ER, HER2 and ALCAM mRNA expression
levels compared with the existing results of IHC and western blot
expression (Kim et al, 2006; Ihnen et al, 2008; Pentheroudakis
et al, 2009). This observation might lead to the assumption that
mRNA expression levels of these markers could function as
prognostic and predictive markers by themselves. Regarding the
most appropriate OPN detection method, SPP1 mRNA expression
analysis appears to be advantageous, as evaluation of OPN protein
expression is constrained by the large number of OPN splice
variants, phosphorylation and glycosylation products, as well as by
differences in specificity of the available antibodies towards these
protein forms (Kon et al, 2000). These reasons led us to the
decision to focus on SPP1, ALCAM, ESR1 and HER2 mRNA
expression in our study.
In conclusion, our marker set algorithm might be instrumental
in identifying receptor-negative patients who are suffering from
particularly high-risk tumours that are unlikely to respond to
therapy regimens as used in our cohorts. These patients could be
candidates for new therapeutic approaches, like targeted therapies
or intensive chemotherapy. Our findings need to be validated in a
larger prospective study, directly comparing mRNA microarray
and kRT–PCR in FFT and FFPE tumour tissues, as kRT–PCR
appears to be a valid and feasible method for quantification of gene
expression and could provide the advantage of being more
applicable in clinical routine use.
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